Cite

HARVARD Citation

    Fuoco, V. et al. (2022). Update on radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: clinical aspects and survival effects. Tumori. 108 (4), pp. 315-325. [Online]. 
  
Back to record